Research Unit for Health Trials
Bergen, 5009, Norway
NCT Number: NCT05149079
This randomized, double blind, controlled trial investigates changes in the cardiovascular index (triacylglycerol/HDL-cholesterol × waist/hip ratio) after 12 weeks of marine protein hydrolysate (MPH) or whey protein powder (placebo) supplementation in adult healthy persons. Additionally, the study investigates potential effects on plasma parameters of metabolic health including lipids, glucose, inflammatory parameters and redox state, as well as associations between dietary MPH and body weight, abdominal obesity, body composition, and gut microbiota composition. Finally, putative end-products of diet-microbial interactions (TMAO and short-chain fatty acids) with CVD risk factors and biomarkers of mitochondrial function are examined.
Looking for future studies?
Notify Me20 year–80 year
All sexes
Interventional
Not applicable
Bergen, 5009, Norway
Marine protein sources, including fish and fish protein hydrolysates, may have particular health benefits. Health benefits from fish consumption have been attributed to the n-3 polyunsaturated fatty acids, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Proteins from marine sources may contain valuable bioactive components, with amino acid composition and protein profiles that differ from terrestrial sources. Generally, the dietary source of protein can affect cellular energy metabolism, and hydrolyzed peptides can have potent and specific bioactive potential.
Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM were treated with enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption. The investigational products are given in a dose of 18 g protein per day, corresponding to the protein content of a standard meal, and similar to doses recommended in a range of protein supplements.
The study enrolls around 70 men and women age of 20-80 years with waist circumference of < 102 cm for men and < 88 cm for women. Prospective study participants were informed of the study and invited to participate through advertising primarily in social media (Facebook advertisement, geographically limited to 12 km surrounding the city centers of Bergen and Ålesund). Participants provided written informed consent, and were screened via self-reporting in an online form in EasyTrial hosted by the Research Unit for Clinical Trials at the University of Bergen. Data collection by the study staff at baseline verifies inclusion and exclusion criteria and participant eligibility prior to randomization. The potential participants are informed about practical details at a digital or physical meeting 1-2 weeks prior to baseline.
Groups of participants (40-60% males/females) are block randomized to the two treatments using randomly selected block sizes, and stratified according to sex.
The participants are given a container with the powder sufficient for the entire study period, and a spoon to measure the intake at breakfast (6 g), lunch (6 g) and supper (6 g), or morning (9 g) and evening (9 g) according to individual preference. The patients will mix the powder products in water or mineral water. Flavours have been masked by supplementation with beet powder, and mixing 0.5 g fish hydrolysate per serving in the placebo, to minimize differences in taste of the placebo and active product.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.
Whey protein powder, commercially available
Other names: Whey protein powder
Time frame: Baseline to 12 weeks
Triacylclygerol and HDL-cholesterol concentrations will be measured in serum. Waist and hip circumference will be measured using anthropometric tape over light clothing. For waist circumference, the minimum circumference between the iliac crest and the rib cage will be used. For waist circumference the circumference at the level of the greatest protrusion of the buttocks is used.
Time frame: Baseline to 12 weeks
Measured in serum and calculated as 1 / (log(fasting insulin μU/mL) + log(fasting glucose mg/dL)
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured in serum
Time frame: Baseline to 12 weeks
Measured by 16S sequencing
Time frame: Baseline to 12 weeks
Faecal SCFA concentrations calculated as (mmol/L) × wet faecal weight x faecal moisture content (g/100 g) × 10
Time frame: Baseline to 12 weeks
Body composition measured by bioimpedance analysis
Time frame: Baseline to 12 weeks
Waist and hip circumference will be measured using anthropometric tape over light clothing. For waist circumference, the minimum circumference between the iliac crest and the rib cage will be used. For waist circumference the circumference at the level of the greatest protrusion of the buttocks is used
Time frame: Baseline to 12 weeks
Waist circumference will be measured using anthropometric tape over light clothing. Hight will be measured using a stadiometer. For waist circumference, the minimum circumference between the iliac crest and the rib cage will be used.
Time frame: Baseline to 12 weeks
Blood pressure measurement will be performed manually by a trained nurse using standard equipment
Time frame: Baseline to 12 weeks
Heart rate will be determined manually by a trained nurse
Time frame: Baseline to 12 weeks
Measured in plasma by ELISA (enzyme-linked immunosorbent assay)
Time frame: Baseline to 12 weeks
Measured in plasma by ELISA (enzyme-linked immunosorbent assay)
Time frame: Baseline to 12 weeks
Measured in plasma by ELISA (enzyme-linked immunosorbent assay)
University of Bergen
Other
Randomized, Double Blind, Placebo Controlled Clinical Study to Investigate the Effect of a Marine Protein Hydrolysate in Healthy Adults
Acronym: MARPEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04329962
Healthy Diet, Nutrition Aspect of Cancer
Columbus, Ohio, United States
View Trial DetailsNCT06648226
Behavior, Behavior, Animal
Palo Alto, California, United States
View Trial DetailsNCT05870930
Healthy Diet
Athens, Greece
View Trial DetailsNCT07344870
Adolescent, Athletic Performance
Burdur, Turkey (Türkiye)
View Trial Details